Diamyd Medical AB (publ) (STO:DMYD.B)

Sweden flag Sweden · Delayed Price · Currency is SEK
9.62
-0.26 (-2.63%)
At close: Dec 5, 2025
-34.56%
Market Cap 1.32B
Revenue (ttm) 130.00K
Net Income (ttm) -169.78M
Shares Out 137.50M
EPS (ttm) -1.51
PE Ratio n/a
Forward PE 20.47
Dividend n/a
Ex-Dividend Date n/a
Volume 342,040
Average Volume 355,142
Open 9.86
Previous Close 9.88
Day's Range 9.54 - 9.98
52-Week Range 7.50 - 19.50
Beta 1.76
RSI 47.54
Earnings Date Nov 13, 2025

About Diamyd Medical AB

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to devel... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1984
Employees 39
Stock Exchange Nasdaq Stockholm
Ticker Symbol DMYD.B
Full Company Profile

Financial Performance

In 2025, Diamyd Medical AB's revenue was 130,000, a change of 0.00% compared to the previous year's 130,000. Losses were -169.78 million, 11.8% more than in 2024.

Financial Statements

News

Diamyd Medical AB (publ) (DYMDF) Panel Discussion on Advances and Challenges in Type 1 Diabetes for World Diabetes Day Transcript

Diamyd Medical AB (publ) (OTC:DYMDF) Panel Discussion on Advances and Challenges in Type 1 Diabetes for World Diabetes Day November 14, 2025 7:00 AM...

21 days ago - Seeking Alpha